Orthopedics Medical News about Glucosamine sulfate, Knee osteoarthritis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled trial
Current Therapeutic Research, 07/28/09

Giordano N et al. – Study reports that glucosamine sulfate (GS) 1500 mg QD PO for 12 wks was associated with statistically significant reductions in pain and improvements in functioning, with decreased analgesic consumption, compared with baseline and placebo in pts with knee osteoarthritis (OA). A carryover effect was detected after treatment ended.

Methods

Aim was to assess the efficacy and tolerability of GS in the treatment of knee OA
Consecutive outpatients (n=60); affected by primary monolateral or bilateral knee OA, randomized to:
- GS 1500 mg QD for 12 weeks, (n=30) and
- Placebo QD for 12 wks (n=30)
Treatment period was followed by a 12-wk treatment-free observation phase
Each patient was examined at baseline and at wks 4, 8, 12, 16, 20, and 24
Primary efficacy criteria: pain at rest and during movement, assessed on VAS of 0-100 mm
Secondary criteria: WOMAC index for total pain score (W-TPS), total stiffness score (W-TSS), and total physical function score (W-TPFS)
VAS, W-TPS, W-TSS, and W-TPFS were evaluated at baseline and at wks 4, 8, 12, 16, 20, and 24
Analgesic drug consumption (ie, acetaminophen or NSAIDs) was also assessed

Results

Patient demographics were similar in the GS and placebo groups
56/60 pts completed the study (28 with GS and 28 who received placebo)
An improvements in symptomatic knee OA were observed, as measured by differences in resting pain at wks 8, 12, and 16 and in pain during movement at wks 12 and 16
W-TPS was lower with GS than placebo at wks 8, 12, and 16, and at wk 20
W-TSS was also lower with GS than placebo at wks 8, 12, 16, and 20
W-TPFS was lower with GS than placebo at wks 8, 12, 16, and 20
Drug consumption was lower in the GS group vs placebo group at wks 8, 12, 16, and 20
Incidence of AEs was 36.7% with GS and 40.0% with placebo

<< Previous
Pulsed electromagnetic field treatment for fracture healing

Next >>
Should tourniquets be used in upper limb surgery ? A systematic...

Cartilage loss occurs in the same subregions as subchondral bone attrition: A within-knee subregion-matched approach from the multicenter osteoarthritis study
Arthritis Care and Research, 11/05/09 Relevance Score: 69%

Knee Extension and Flexion Weakness in People With Knee Osteoarthritis: Is Antagonist Cocontraction a Factor
Journal of Orthopaedic & Sports Physical Therapy, 11/02/09 Relevance Score: 69%

The Safety of Flavocoxid, a Medical Food, in the Dietary Management of Knee Osteoarthritis
Journal of Medicinal Food, 10/30/09 Relevance Score: 69%

Knee Extension and Flexion Weakness in People With Knee Osteoarthritis: Is Antagonist Co-contraction a Factor
Journal of Orthopaedic & Sports Physical Therapy, 10/26/09 Relevance Score: 69%

Effect of nonsteroidal anti-inflammatory drug plasters for knee osteoarthritis in Japanese: a randomized controlled trial
Modern Rheumatology, 10/12/09 Relevance Score: 69%